The pharma powerhouse which employs about 5,000 workers across Ireland - at bases in Cork, Dublin and Kildare - has ...

Pfizer has today reported higher-than-expected third quarter profit due to strong sales of Covid-19 treatment Paxlovid, an ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at ... But despite the cultural ubiquity, Viagra has recently faced the inevitable threat from competition ...

Bourla made his first public comments on Starboard's criticism of management on a conference call to discuss the financial ...

Approval of Hympavzi expands Pfizer’s portfolio of hemophilia medicines months after the company secured U.S. clearance of a gene therapy for the B form of the condition. Another of the company’s gene ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication. On Friday, the FDA signed ...

Starboard’s exact plan for Pfizer is not known but Wall Street’s frustration with the Viagra maker is. Under Bourla’s leadership, Pfizer bet all its chips on the Covid-19 pandemic and then ...

Pfizer, facing down a contentious challenge from an activist investor, reported earnings for the third quarter Tuesday that handily beat Wall Street forecasts and led it to boost revenue guidance for ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Pfizer stock (NYSE: PFE) currently trades at $29 per share, 45% below its peak level of $54 seen in December 2021. In contrast, Merck stock is up 54% over this period. PFE stock was trading at $47 ...

Good morning. China neglected to put numbers on its stimulus plan over the weekend — again. There are a few other opportunities coming up for the central government to announce the specifics ...

Pfizer's dividend is expected to grow slowly for the next few years as it normalizes its earnings and brings the payout ratio down to a safe sub-60 % level. Rating agencies say the average payout ...